BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Verbeek RE, Leenders M, Ten Kate FJ, van Hillegersberg R, Vleggaar FP, van Baal JW, van Oijen MG, Siersema PD. Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterol. 2014;109:1215-1222. [PMID: 24980881 DOI: 10.1038/ajg.2014.156] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Goldberg A, Gerkin RD, Young M. Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins. Dig Dis Sci 2015;60:2058-62. [PMID: 25680872 DOI: 10.1007/s10620-015-3569-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
2 Ding YE, Li Y, He XK, Sun LM. Impact of Barrett's esophagus surveillance on the prognosis of esophageal adenocarcinoma: A meta-analysis. J Dig Dis 2018;19:737-44. [PMID: 30375167 DOI: 10.1111/1751-2980.12682] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology. 2015;149:302-17.e1. [PMID: 25957861 DOI: 10.1053/j.gastro.2015.04.053] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 26.0] [Reference Citation Analysis]
4 Gaur P, Kim MP, Dunkin BJ. Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog 2014;13:11. [PMID: 25395880 DOI: 10.4103/1477-3163.143720] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
5 Halland M, Katzka D, Iyer PG. Recent developments in pathogenesis, diagnosis and therapy of Barrett's esophagus. World J Gastroenterol 2015; 21(21): 6479-6490 [PMID: 26074687 DOI: 10.3748/wjg.v21.i21.6479] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kurtom S, Kaplan BJ. Esophagus and Gastrointestinal Junction Tumors. Surg Clin North Am 2020;100:507-21. [PMID: 32402297 DOI: 10.1016/j.suc.2020.02.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88-95. [PMID: 26851752 DOI: 10.1016/j.canep.2016.01.013] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 21.0] [Reference Citation Analysis]
8 Tan MC, Mansour N, White DL, Sisson A, El-Serag HB, Thrift AP. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther 2020;52:20-36. [PMID: 32452599 DOI: 10.1111/apt.15760] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
9 Younes M, Brown K, Lauwers GY, Ergun G, Meriano F, Schmulen AC, Barroso A, Ertan A. p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients. Histopathology 2017;71:27-33. [PMID: 28226185 DOI: 10.1111/his.13193] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
10 Schmidt M, Hackett RJ, Baker AM, McDonald SAC, Quante M, Graham TA. Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34728819 DOI: 10.1038/s41575-021-00531-4] [Reference Citation Analysis]
11 Yusuf A, Fitzgerald RC. Screening for Barrett's Oesophagus: Are We Ready for it? Curr Treat Options Gastroenterol 2021;:1-16. [PMID: 33746508 DOI: 10.1007/s11938-021-00342-1] [Reference Citation Analysis]
12 Ferrer-Torres D, Nancarrow DJ, Kuick R, Thomas DG, Nadal E, Lin J, Chang AC, Reddy RM, Orringer MB, Taylor JM, Wang TD, Beer DG. Genomic similarity between gastroesophageal junction and esophageal Barrett's adenocarcinomas. Oncotarget 2016;7:54867-82. [PMID: 27363029 DOI: 10.18632/oncotarget.10253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
13 Nguyen T, Thrift AP, Yu X, Duan Z, El-Serag HB. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol 2017;112:1049-55. [PMID: 28244499 DOI: 10.1038/ajg.2017.18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
14 de Vegt F, Gommers JJJ, Groenewoud H, Siersema PD, Verbeek ALM, Peters Y, Broeders MJM. Trends and projections in the incidence of oesophageal cancer in the Netherlands: An age-period-cohort analysis from 1989 to 2041. Int J Cancer 2022;150:420-30. [PMID: 34605022 DOI: 10.1002/ijc.33836] [Reference Citation Analysis]
15 Tontini GE, Neumann H. Artificial intelligence: Thinking outside the box. Best Pract Res Clin Gastroenterol 2021;52-53:101720. [PMID: 34172247 DOI: 10.1016/j.bpg.2020.101720] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Krishnamoorthi R, Borah B, Heien H, Das A, Chak A, Iyer PG. Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc 2016;84:40-46.e7. [PMID: 26772891 DOI: 10.1016/j.gie.2015.12.036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
17 Sawas T, Iyer PG, Alsawas M, Cotton CC, Leggett CL, Murad MH, Wang KK, Shaheen NJ, Katzka DA. Higher Rate of Barrett's Detection in the First Year After Successful Endoscopic Therapy: Meta-analysis. American Journal of Gastroenterology 2018;113:959-71. [DOI: 10.1038/s41395-018-0090-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
18 Grin A, Samaan S, Tripathi M, Rotondo F, Kovacs K, Bassily MN, Yousef GM. Evaluation of human tissue kallikrein-related peptidases 6 and 10 expression in early gastroesophageal adenocarcinoma. Hum Pathol 2015;46:541-8. [PMID: 25649006 DOI: 10.1016/j.humpath.2014.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
19 Bibbò S, Ianiro G, Ricci R, Arciuolo D, Petruzziello L, Spada C, Larghi A, Riccioni ME, Gasbarrini A, Costamagna G, Cammarota G. Barrett's oesophagus and associated dysplasia are not equally distributed within the esophageal circumference. Digestive and Liver Disease 2016;48:1043-7. [DOI: 10.1016/j.dld.2016.06.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Singer ME, Smith MS. Wide Area Transepithelial Sampling with Computer-Assisted Analysis (WATS3D) Is Cost-Effective in Barrett's Esophagus Screening. Dig Dis Sci 2021;66:1572-9. [PMID: 32578042 DOI: 10.1007/s10620-020-06412-1] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Critchley-Thorne RJ, Davison JM, Prichard JW, Reese LM, Zhang Y, Repa K, Li J, Diehl DL, Jhala NC, Ginsberg GG, DeMarshall M, Foxwell T, Jobe BA, Zaidi AH, Duits LC, Bergman JJ, Rustgi A, Falk GW. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 2017;26:240-8. [PMID: 27729357 DOI: 10.1158/1055-9965.EPI-16-0640] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
22 Wani S, Gaddam S. Editorial: Best Practices in Surveillance of Barrett's Esophagus. Am J Gastroenterol 2017;112:1056-60. [PMID: 28725066 DOI: 10.1038/ajg.2017.117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
23 Pereira AD, Chaves P. Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J 2016;4:343-52. [PMID: 27403300 DOI: 10.1177/2050640615612409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Januszewicz W, Fitzgerald RC. Barrett's oesophagus and oesophageal adenocarcinoma. Medicine (Abingdon) 2019;47:275-85. [PMID: 32467662 DOI: 10.1016/j.mpmed.2019.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016;111:30-50; quiz 51. [PMID: 26526079 DOI: 10.1038/ajg.2015.322] [Cited by in Crossref: 793] [Cited by in F6Publishing: 630] [Article Influence: 113.3] [Reference Citation Analysis]
26 Holmberg D, Ness-jensen E, Mattsson F, El-serag HB, Lagergren J. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. European Journal of Cancer 2017;75:41-6. [DOI: 10.1016/j.ejca.2016.12.037] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
27 Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C. The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. Am J Gastroenterol 2017;112:1256-64. [PMID: 28374815 DOI: 10.1038/ajg.2017.82] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
28 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. [PMID: 25651787 DOI: 10.3322/caac.21262] [Cited by in Crossref: 16506] [Cited by in F6Publishing: 17144] [Article Influence: 2358.0] [Reference Citation Analysis]
29 Waterhouse DJ, Fitzpatrick CRM, di Pietro M, Bohndiek SE. Emerging optical methods for endoscopic surveillance of Barrett's oesophagus. The Lancet Gastroenterology & Hepatology 2018;3:349-62. [DOI: 10.1016/s2468-1253(18)30030-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
30 Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. J Clin Gastroenterol 2018;52:401-6. [PMID: 28422774 DOI: 10.1097/MCG.0000000000000790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
31 Martinucci I, de Bortoli N, Russo S, Bertani L, Furnari M, Mokrowiecka A, Malecka-Panas E, Savarino V, Savarino E, Marchi S. Barrett’s esophagus in 2016: From pathophysiology to treatment. World J Gastrointest Pharmacol Ther 2016; 7(2): 190-206 [PMID: 27158534 DOI: 10.4292/wjgpt.v7.i2.190] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
32 Otaki F, Iyer PG. Point-Counterpoint: Screening and Surveillance for Barrett's Esophagus, Is It Worthwhile? Dig Dis Sci 2018;63:2081-93. [PMID: 29713986 DOI: 10.1007/s10620-018-5065-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Snider EJ, Compres G, Freedberg DE, Giddins MJ, Khiabanian H, Lightdale CJ, Nobel YR, Toussaint NC, Uhlemann AC, Abrams JA. Barrett's esophagus is associated with a distinct oral microbiome. Clin Transl Gastroenterol. 2018;9:135. [PMID: 29491399 DOI: 10.1038/s41424-018-0005-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
34 Pan W, Li X, Wang W, Zhou L, Wu J, Ren T, Liu C, Lv M, Su S, Tang Y. Identification of Barrett's esophagus in endoscopic images using deep learning. BMC Gastroenterol 2021;21:479. [PMID: 34920705 DOI: 10.1186/s12876-021-02055-2] [Reference Citation Analysis]
35 Guan CT, Song GH, Li BY, Gong YW, Hao CQ, Xue LY, Chen WQ, Wei WQ. Endoscopy screening effect on stage distributions of esophageal cancer: A cluster randomized cohort study in China. Cancer Sci 2018;109:1995-2002. [PMID: 29635717 DOI: 10.1111/cas.13606] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
36 Bus P, Kestens C, Ten Kate FJ, Peters W, Drenth JP, Roodhart JM, Siersema PD, van Baal JW. Profiling of circulating microRNAs in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol. 2016;51:560-570. [PMID: 26585599 DOI: 10.1007/s00535-015-1133-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
37 Whitson MJ, Falk GW. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus. Gastroenterol Clin North Am 2015;44:299-315. [PMID: 26021196 DOI: 10.1016/j.gtc.2015.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
38 El-Serag HB, Naik AD, Duan Z, Shakhatreh M, Helm A, Pathak A, Hinojosa-Lindsey M, Hou J, Nguyen T, Chen J, Kramer JR. Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma detected in patients with Barrett's oesophagus. Gut 2016;65:1252-60. [PMID: 26311716 DOI: 10.1136/gutjnl-2014-308865] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 10.9] [Reference Citation Analysis]
39 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
40 Faqih A, Broman KK, Huang LC, Phillips SE, Holzman MD, Pierce RA, Poulose BK, Yachimski PS. Frequency of endoscopic surveillance for Barrett's esophagus is influenced by health insurance status: results from a population-based analysis. Dis Esophagus 2017;30:1-8. [PMID: 28881902 DOI: 10.1093/dote/dox080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
41 Krishnamoorthi R, Singh S, Ragunathan K, Visrodia K, Wang KK, Katzka DA, Iyer PG. Factors Associated With Progression of Barrett’s Esophagus: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:1046-1055.e8. [DOI: 10.1016/j.cgh.2017.11.044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
42 De Silva N, Fitzgerald R. Barrett's oesophagus and oesophageal adenocarcinoma. Medicine 2015;43:202-9. [DOI: 10.1016/j.mpmed.2015.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Kamboj AK, Katzka DA, Iyer PG. Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges. Gastrointest Endosc Clin N Am 2021;31:27-41. [PMID: 33213798 DOI: 10.1016/j.giec.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Baldwin-Hunter BL, Knotts RM, Leeds SD, Rubenstein JH, Lightdale CJ, Abrams JA. Use of the Electronic Health Record to Target Patients for Non-endoscopic Barrett's Esophagus Screening. Dig Dis Sci 2019;64:3463-70. [PMID: 31273597 DOI: 10.1007/s10620-019-05707-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
45 Omidvari AH, Meester RG, Lansdorp-Vogelaar I. Cost effectiveness of surveillance for GI cancers. Best Pract Res Clin Gastroenterol. 2016;30:879-891. [PMID: 27938783 DOI: 10.1016/j.bpg.2016.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
46 Lochhead P, Chan AT. Screening and surveillance for Barrett esophagus. JAMA Intern Med 2015;175:159-60. [PMID: 25546002 DOI: 10.1001/jamainternmed.2014.6983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
47 Vaughan TL, Fitzgerald RC. Precision prevention of oesophageal adenocarcinoma. Nat Rev Gastroenterol Hepatol. 2015;12:243-248. [PMID: 25666644 DOI: 10.1038/nrgastro.2015.24] [Cited by in Crossref: 90] [Cited by in F6Publishing: 85] [Article Influence: 12.9] [Reference Citation Analysis]
48 Blevins CH, Iyer PG. Who Deserves Endoscopic Screening for Esophageal Neoplasia? Gastrointest Endosc Clin N Am. 2017;27:365-378. [PMID: 28577762 DOI: 10.1016/j.giec.2017.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
49 Tytgat GN. Reflections on esophageal columnar metaplasia (Barrett)-ANNO 2015. J Dig Dis 2015;16:55-7. [PMID: 25529483 DOI: 10.1111/1751-2980.12224] [Reference Citation Analysis]
50 Kaul V, Gross S, Corbett FS, Malik Z, Smith MS, Tofani C, Infantolino A. Clinical utility of wide-area transepithelial sampling with three-dimensional computer-assisted analysis (WATS3D) in identifying Barrett's esophagus and associated neoplasia. Dis Esophagus 2020;33:doaa069. [PMID: 32607543 DOI: 10.1093/dote/doaa069] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Shiota S, El-Serag HB, Thrift AP. Premature Birth and Large for Gestational Age Are Associated with Risk of Barrett's Esophagus in Adults. Dig Dis Sci 2016;61:1139-47. [PMID: 26611860 DOI: 10.1007/s10620-015-3967-3] [Reference Citation Analysis]
52 Rubenstein JH. Surveillance in Barrett's Esophagus: Utility and Current Recommendations. Gastroenterol Clin North Am 2015;44:285-97. [PMID: 26021195 DOI: 10.1016/j.gtc.2015.02.004] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Peters Y, Siersema PD. Public Preferences and Predicted Uptake for Esophageal Cancer Screening Strategies: A Labeled Discrete Choice Experiment. Clin Transl Gastroenterol 2020;11:e00260. [PMID: 33105164 DOI: 10.14309/ctg.0000000000000260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Qiao Y, Hyder A, Bae SJ, Zarin W, O'Neill TJ, Marcon NE, Stein L, Thein HH. Surveillance in Patients With Barrett's Esophagus for Early Detection of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol 2015;6:e131. [PMID: 26658838 DOI: 10.1038/ctg.2015.58] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
55 Peters Y, Al-kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD. Barrett oesophagus. Nat Rev Dis Primers 2019;5. [DOI: 10.1038/s41572-019-0086-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
56 Yang Y, Chen H, Wang R, Tang Y, Chen X. Cost-Effectiveness Analysis on Endoscopic Surveillance Among Western Patients With Barrett's Esophagus for Esophageal Adenocarcinoma Screening. Medicine 2015;94:e1563. [DOI: 10.1097/md.0000000000001563] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
57 Jung HK, Tae CH, Song KH, Kang SJ, Park JK, Gong EJ, Shin JE, Lim HC, Lee SK, Jung DH, Choi YJ, Seo SI, Kim JS, Lee JM, Kim BJ, Kang SH, Park CH, Choi SC, Kwon JG, Park KS, Park MI, Lee TH, Kim SY, Cho YS, Lee HH, Jung KW, Kim DH, Moon HS, Miwa H, Chen CL, Gonlachanvit S, Ghoshal UC, Wu JCY, Siah KTH, Hou X, Oshima T, Choi MY, Lee KJ; Korean Society of Neurogastroenterology and Motility. 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. J Neurogastroenterol Motil 2021;27:453-81. [PMID: 34642267 DOI: 10.5056/jnm21077] [Reference Citation Analysis]
58 Hamade N, Kamboj AK, Krishnamoorthi R, Singh S, Hassett LC, Katzka DA, Kahi CJ, Fatima H, Iyer PG. Systematic review with meta-analysis: neoplasia detection rate and post-endoscopy Barrett's neoplasia in Barrett's oesophagus. Aliment Pharmacol Ther 2021;54:546-59. [PMID: 34275161 DOI: 10.1111/apt.16531] [Reference Citation Analysis]
59 Saxena N, Inadomi JM. Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance. Gastrointestinal Endoscopy Clinics of North America 2017;27:397-421. [DOI: 10.1016/j.giec.2017.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Michopoulos S. Critical appraisal of guidelines for screening and surveillance of Barrett's esophagus. Ann Transl Med 2018;6:259. [PMID: 30094245 DOI: 10.21037/atm.2018.05.09] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Le Bras GF, Farooq MH, Falk GW, Andl CD. Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res 2016;113:236-44. [PMID: 27565381 DOI: 10.1016/j.phrs.2016.08.021] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
62 Old OJ, Almond LM, Barr H. Barrett's oesophagus: how should we manage it? Frontline Gastroenterol 2015;6:108-16. [PMID: 28839797 DOI: 10.1136/flgastro-2014-100552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Holmberg D, Ness-Jensen E, Mattsson F, Lagergren J. Clinical prediction model for tumor progression in Barrett's esophagus. Surg Endosc 2019;33:2901-8. [PMID: 30456503 DOI: 10.1007/s00464-018-6590-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Peters Y, van Grinsven E, van de Haterd M, van Lankveld D, Verbakel J, Siersema PD. Individuals’ Preferences for Esophageal Cancer Screening: A Discrete Choice Experiment. Value in Health 2020;23:1087-95. [DOI: 10.1016/j.jval.2020.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Maslyonkina KS, Konyukova AK, Alexeeva DY, Sinelnikov MY, Mikhaleva LM. Barrett's esophagus: The pathomorphological and molecular genetic keystones of neoplastic progression. Cancer Med 2021. [PMID: 34870375 DOI: 10.1002/cam4.4447] [Reference Citation Analysis]
66 Waterhouse DJ, Fitzpatrick CRM, Pogue BW, O’connor JPB, Bohndiek SE. A roadmap for the clinical implementation of optical-imaging biomarkers. Nat Biomed Eng 2019;3:339-53. [DOI: 10.1038/s41551-019-0392-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
67 Eluri S, Shaheen NJ. Barrett's esophagus: diagnosis and management. Gastrointest Endosc. 2017;85:889-903. [PMID: 28109913 DOI: 10.1016/j.gie.2017.01.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
68 Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150:599-607.e7; quiz e14-5. [PMID: 26619962 DOI: 10.1053/j.gastro.2015.11.040] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 10.3] [Reference Citation Analysis]
69 Triggs JR, Falk GW. Best Practices in Surveillance for Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:59-75. [PMID: 33213800 DOI: 10.1016/j.giec.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Old O, Moayyedi P, Love S, Roberts C, Hapeshi J, Foy C, Stokes C, Briggs A, Jankowski J, Barr H; the BOSS Trial Team. Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. J Med Screen 2015;22:158-64. [DOI: 10.1177/0969141315575052] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
71 Quante M, Wang TC, Bass AJ. Adenocarcinoma of the oesophagus: is it gastric cancer? Gut 2022:gutjnl-2022-327096. [PMID: 35365571 DOI: 10.1136/gutjnl-2022-327096] [Reference Citation Analysis]
72 Chan MQ, Blum AE, Chandar AK, Emmons AMLK, Shindo Y, Brock W, Falk GW, Canto MI, Wang JS, Iyer PG, Shaheen NJ, Grady WM, Abrams JA, Thota PN, Guda KK, Chak A. Association of sporadic and familial Barrett's esophagus with breast cancer. Dis Esophagus 2018;31. [PMID: 29528378 DOI: 10.1093/dote/doy007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Ness-Jensen E. Epidemiology and prevention of oesophageal adenocarcinoma. Scand J Gastroenterol 2022;:1-5. [PMID: 35234549 DOI: 10.1080/00365521.2022.2042594] [Reference Citation Analysis]
74 Golger D, Probst A, Messmann H. Barrett's esophagus: lessons from recent clinical trials. Ann Gastroenterol 2016;29:417-23. [PMID: 27708506 DOI: 10.20524/aog.2016.0070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Borgmann M, Quante M. Impact of the Tumor Microenvironment for Esophageal Tumor Development—An Opportunity for Prevention? Cancers 2022;14:2246. [DOI: 10.3390/cancers14092246] [Reference Citation Analysis]
76 Peters Y, Huibertse LJ, Schrauwen RWM, Tan AC, van der Post RS, Siersema PD. Increased risk of Barrett's oesophagus and related neoplasia in individuals with a positive family history. Eur J Cancer 2021;155:116-26. [PMID: 34375895 DOI: 10.1016/j.ejca.2021.07.007] [Reference Citation Analysis]
77 Groulx S, Limburg H, Doull M, Klarenbach S, Singh H, Wilson BJ, Thombs B; Canadian Task Force on Preventive Health Care. Guideline on screening for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease. CMAJ 2020;192:E768-77. [PMID: 32631908 DOI: 10.1503/cmaj.190814] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, Chak A, Iyer PG. The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. Gastroenterology 2018;154:2068-2086.e5. [PMID: 29458154 DOI: 10.1053/j.gastro.2018.02.022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 15.3] [Reference Citation Analysis]
79 Shariff MK, Varghese S, O'Donovan M, Abdullahi Z, Liu X, Fitzgerald RC, di Pietro M. Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett's esophagus. Endoscopy. 2016;48:110-116. [PMID: 26535563 DOI: 10.1055/s-0034-1393310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
80 Machicado JD, Han S, Yadlapati RH, Simon VC, Qumseya BJ, Sultan S, Kushnir VM, Komanduri S, Rastogi A, Muthusamy VR, Haidry R, Ragunath K, Singh R, Hammad HT, Shaheen NJ, Wani S. A Survey of Expert Practice and Attitudes Regarding Advanced Imaging Modalities in Surveillance of Barrett's Esophagus. Dig Dis Sci 2018;63:3262-71. [PMID: 30178283 DOI: 10.1007/s10620-018-5257-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Al-Kaabi A, Baranov NS, van der Post RS, Schoon EJ, Rosman C, van Laarhoven HWM, Verheij M, Verhoeven RHA, Siersema PD. Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study. Acta Oncol 2022;:1-8. [PMID: 35112634 DOI: 10.1080/0284186X.2021.2024878] [Reference Citation Analysis]
82 Thrift AP. Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clinical Gastroenterology and Hepatology 2015;13:2225-32. [DOI: 10.1016/j.cgh.2015.03.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
83 Offman J, Fitzgerald RC. Alternatives to Traditional Per-Oral Endoscopy for Screening. Gastrointest Endosc Clin N Am 2017;27:379-96. [PMID: 28577763 DOI: 10.1016/j.giec.2017.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
84 Knotts RM, Solfisburg QS, Keating C, DiMango E, Lightdale CJ, Abrams JA. Cystic fibrosis is associated with an increased risk of Barrett's esophagus. J Cyst Fibros. 2019;18:425-429. [PMID: 30473189 DOI: 10.1016/j.jcf.2018.11.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
85 Visrodia K, Iyer PG, Schleck CD, Zinsmeister AR, Katzka DA. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study. Dig Dis Sci 2016;61:158-67. [PMID: 25956705 DOI: 10.1007/s10620-015-3697-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
86 Cummings LC, Kou TD, Chak A, Schluchter MD, Margevicius S, Cooper GS. Receipt of Serial Endoscopy Procedures Prior to Esophageal Adenocarcinoma Diagnosis Is Associated with Better Survival. Dig Dis Sci 2021. [PMID: 33881677 DOI: 10.1007/s10620-021-06927-1] [Reference Citation Analysis]
87 Honing J, di Pietro M. Surveillance for Barrett's esophagus: let's get the basics right. Gastrointest Endosc 2021:S0016-5107(21)01701-6. [PMID: 34863470 DOI: 10.1016/j.gie.2021.10.003] [Reference Citation Analysis]
88 Moriarty JP, Shah ND, Rubenstein JH, Blevins CH, Johnson M, Katzka DA, Wang KK, Wongkeesong LM, Ahlquist DA, Iyer PG. Costs associated with Barrett's esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointest Endosc. 2018;87:88-94.e2. [PMID: 28455158 DOI: 10.1016/j.gie.2017.04.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
89 Fock KM, Talley N, Goh KL, Sugano K, Katelaris P, Holtmann G, Pandolfino JE, Sharma P, Ang TL, Hongo M, Wu J, Chen M, Choi MG, Law NM, Sheu BS, Zhang J, Ho KY, Sollano J, Rani AA, Kositchaiwat C, Bhatia S. Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus. Gut. 2016;65:1402-1415. [PMID: 27261337 DOI: 10.1136/gutjnl-2016-311715] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
90 Patel A, Gyawali CP. Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness. J Neurogastroenterol Motil 2019;25:181-8. [PMID: 30827080 DOI: 10.5056/jnm18156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
91 Tavakkoli A, Appelman HD, Beer DG, Madiyal C, Khodadost M, Nofz K, Metko V, Elta G, Wang T, Rubenstein JH. Use of Appropriate Surveillance for Patients With Nondysplastic Barrett's Esophagus. Clin Gastroenterol Hepatol 2018; 16: 862-869. e3. [PMID: 29432922 DOI: 10.1016/j.cgh.2018.01.052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
92 Barrie J, Yanni F, Sherif M, Dube AK, Tamhankar AP. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. Surg Endosc 2021;35:4756-62. [PMID: 32880012 DOI: 10.1007/s00464-020-07950-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]